Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
News|Articles|July 1, 2013
Mass Spec Software Optimizes Biopharmaceutical Characterization
Author(s)Pharmaceutical Technology Editors
Agilent Technologies Inc. introduced the MassHunter BioConfirm application, which allows users to rapidly create targeted screening methods.
Agilent Technologies Inc. introduced the MassHunter BioConfirm application, which allows users to rapidly create targeted screening methods to characterize intact proteins and biosimilars for biopharmaceutical research,
MassHunter BioConfirm software provides mirror plots for the comparison of biosimilars and peak modeling deconvolution to determine the molecular weight of intact proteins. The peak-modeling algorithm removes artifacts from a mass spectrum and helps resolve overlapped peaks. The resulting (simplified) spectra then allow researchers to visualize the precision of the mass measurement and ensure the accuracy of their results. This enables rapid confirmation of intact protein sequences and modifications.
Agilent’s MassHunter Workstation portfolio includes 20 individual software applications designed to optimize instrument control, data acquisition and qualitative/quantitative data analysis for Agilent’s time-of-flight, quadrupole time-of-flight, triple quadrupole, and inductively coupled plasma mass spectrometry systems.
Related to this article
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.